WuXi Biologics (Cayman) Inc. Share Price
Equities
2269
KYG970081173
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.44 HKD | -3.11% |
|
-0.55% | +84.74% |
| Capitalization | 12TCr 13TCr 1.72TCr 1.46TCr 1.37TCr 1.29TCr 2.37TCr 1,56100Cr 2.59TCr 16TCr 6.17TCr 73TCr 6.46TCr 6.32TCr 2,67200Cr | P/E ratio 2025 * |
27.2x | P/E ratio 2026 * | 24.1x |
|---|---|---|---|---|---|
| Enterprise value | 12TCr 13TCr 1.63TCr 1.39TCr 1.3TCr 1.22TCr 2.25TCr 1,48200Cr 2.46TCr 15TCr 5.86TCr 70TCr 6.13TCr 6TCr 2,53600Cr | EV / Sales 2025 * |
5.35x | EV / Sales 2026 * | 4.55x |
| Free-Float |
86.37% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: WuXi Biologics (Cayman) Inc.
| 1 day | -3.11% | ||
| 1 week | -0.55% | ||
| Current month | +4.11% | ||
| 1 month | -2.64% | ||
| 3 months | -11.07% | ||
| 6 months | +15.86% | ||
| Current year | +84.74% |
| 1 week | 32.2 |  | 34.56 |
| 1 month | 30.3 | | 34.56 |
| Current year | 15.62 | | 42.6 |
| 1 year | 15.62 | | 42.6 |
| 3 years | 10.14 | | 77.4 |
| 5 years | 10.14 | | 148 |
| 10 years | 8.33 | | 148 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 53 | 01/01/2016 |
Ming Tu
DFI | Director of Finance/CFO | 55 | 23/08/2021 |
Xuejun Gu
CTO | Chief Tech/Sci/R&D Officer | 54 | 31/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Li
CHM | Chairman | 57 | 01/02/2014 |
Zhi Sheng Chen
BRD | Director/Board Member | 53 | 01/02/2014 |
Yan Ling Cao
BRD | Director/Board Member | 41 | 01/05/2016 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 9.62% | 0 M€ | -19.71% | - |
| 4.23% | 0 M€ | -3.45% | - |
| 2.99% | 1 M€ | +14.13% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.11% | -0.55% | +82.25% | -36.14% | 1.78TCr | |
| -3.93% | -6.15% | +24.59% | +96.68% | 5.41TCr | |
| -0.05% | +0.19% | +168.32% | +911.92% | 4.2TCr | |
| -3.02% | +0.90% | +61.43% | +15.98% | 3.96TCr | |
| -1.05% | -2.54% | -22.07% | -49.58% | 2.28TCr | |
| -0.10% | -0.94% | +39.94% | -36.62% | 1.95TCr | |
| -6.67% | -6.37% | +82.56% | +170.86% | 1.47TCr | |
| -1.08% | -6.68% | -6.96% | +385.47% | 1.35TCr | |
| -8.21% | -12.48% | +114.61% | - | 1.31TCr | |
| -1.91% | -1.41% | +80.25% | +791.18% | 1.3TCr | |
| Average | -2.91% | -1.59% | +62.49% | +249.97% | 2.5TCr | |
| Weighted average by Cap. | -2.64% | -1.75% | +64.92% | +251.87% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.15TCr 2.38TCr 305.43Cr 259.7Cr 243.02Cr 228.23Cr 420.49Cr 28TCr 459.42Cr 2.83TCr 1.1TCr 13TCr 1.15TCr 1.12TCr 47TCr | 2.49TCr 2.75TCr 353.45Cr 300.54Cr 281.23Cr 264.12Cr 486.61Cr 32TCr 531.66Cr 3.28TCr 1.27TCr 15TCr 1.33TCr 1.3TCr 55TCr |
| Net income | 445.19Cr 491.63Cr 63Cr 54Cr 50Cr 47Cr 87Cr 5.73TCr 95Cr 586Cr 226.51Cr 2.7TCr 237.04Cr 232.05Cr 9.81TCr | 502.88Cr 555.34Cr 71Cr 61Cr 57Cr 53Cr 98Cr 6.47TCr 107.34Cr 661.94Cr 255.86Cr 3.05TCr 267.75Cr 262.12Cr 11TCr |
| Net Debt | -614.73Cr -678.85Cr -87Cr -74Cr -69Cr -65Cr -120.1Cr -7.91TCr -131.22Cr -809.17Cr -312.77Cr -3.72TCr -327.31Cr -320.42Cr -14TCr | -801.05Cr -884.61Cr -113.67Cr -97Cr -90Cr -85Cr -156.5Cr -10TCr -170.99Cr -1.05TCr -407.56Cr -4.85TCr -426.51Cr -417.53Cr -18TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/25/15 | 32.44 $ | -3.11% | 2,75,71,370 |
| 12/25/12 | 33.48 $ | 0.00% | 2,46,01,320 |
| 11/25/11 | 33.48 $ | -0.30% | 2,36,44,510 |
| 10/25/10 | 33.58 $ | +0.06% | 2,64,32,970 |
| 09/25/09 | 33.56 $ | +1.88% | 4,24,52,550 |
Delayed Quote Hong Kong S.E., December 15, 2025 at 01:38 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2269 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition